U.S. Markets

Moderna (MRNA) reiterates it expects 2026 revenue growth of 15% to 25% (prev. 10%), and is on track to achieve approximately 10ppts of gross margin expansion in 2026, excluding the litigation settlement charge

ORIGINAL · NewsquawkModerna (MRNA) reiterates it expects 2026 revenue growth of 15% to 25% (prev. 10%), and is on track to achieve approximately 10ppts of gross margin expansion in 2026, excluding the litigation settlement chargeRead originalHide original

Commercial growth opportunities in 2027 and beyond include: Seasonal influenza European expansion Strategic partnerships Expanded respiratory portfolio Oncology

StockNow breaking-news AI analysis

Moderna reiterated 2026 revenue growth of 15%–25%; the range was raised from up to 10% after third-quarter results beat analyst expectations.

News detail

Commercial growth opportunities in 2027 and beyond include: Seasonal influenza European expansion Strategic partnerships Expanded respiratory portfolio Oncology

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more